The Board of Directors of CombiGene AB (publ) (”CombiGene” or ”the Company”) has approved a proposal for a preferential rights issue amounting to MSEK 10.2 for existing shareholders (”the Offer” or ”the Rights Issue”). The capital raised via the offer will be used to fund the company’s development of a manufacturing process for CombiGene’s candidate drug, CG01, in collaboration with Cell and Gene Therapy Catapult (CGT Catapult). Collaboration is aimed at developing a complete and finalized manufacturing method that will enable CombiGene to proceed with commercial GMP manufacturing and subsequent clinical trials.
